Evidence map›Paper›PMID 36745791›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2023

Major histocompatibility class I antigenic peptides derived from translation of pre-mRNAs generate immune tolerance.

Ewa Maria Sroka, Mathilde Lavigne, Marika Pla, Chrysoula Daskalogianni, Maria Camila Tovar-Fernandez, Rodrigo Prado Martins, Bénédicte Manoury, Guillaume Darrasse-Jéze, Megane Nascimento, Sebastien Apcher and 1 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Ewa Maria SrokaInternational Centre for Cancer Vaccine Science, University of Gdańsk 80-308, Gdańsk, Poland.ORCID 0000-0002-8315-7446
Mathilde LavigneInstitut National de la Santé et de la Recherche U1131, Institut de Génétique Moléculaire, Université Paris 7 75010, Paris, France.ORCID 0000-0001-7394-2910
Marika PlaInstitut National de la Santé et de la Recherche U1131, Institut de Génétique Moléculaire, Université Paris 7 75010, Paris, France.ORCID 0000-0002-0004-5896
Chrysoula DaskalogianniInternational Centre for Cancer Vaccine Science, University of Gdańsk 80-308, Gdańsk, Poland.ORCID 0000-0001-8177-3141
Maria Camila Tovar-FernandezInternational Centre for Cancer Vaccine Science, University of Gdańsk 80-308, Gdańsk, Poland.ORCID 0000-0001-5398-382X
Rodrigo Prado MartinsInfectiologie, Santé Publique, Institut National de la Recherche Agronomique, Université de Tours, U1282, 37380 Nouzilly, France.ORCID 0000-0002-8213-4015
Bénédicte ManouryInstitut Necker Enfants Malades, Institut National de la Santé et de la Recherche U1151-Centre National de la Recherche Scientifique U8253, Université Paris Cité, 75015 Paris, France.ORCID 0000-0002-4827-4110
Guillaume Darrasse-JézeSorbonne Universite, Institut National de la Santé et de la Recherche, U959, Immunology-Immunopathology-Immunotherapy Laboratory F-75013, Paris, France.ORCID 0000-0003-3069-8211
Megane NascimentoInstitut Gustave Roussy, Université Paris Sud, U1015, 94800 Villejuif, France.
Sebastien ApcherInstitut Gustave Roussy, Université Paris Sud, U1015, 94800 Villejuif, France.ORCID 0000-0002-4434-5022
Robin FåhraeusInstitut National de la Santé et de la Recherche U1131, Institut de Génétique Moléculaire, Université Paris 7 75010, Paris, France.
Université Paris Cité · FRUniversité Paris-Sud · FRDélégation Paris 5 · FRUniversité de Tours · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antigenic peptides derived from introns are presented on major histocompatibility (MHC) class I molecules, but how these peptides are produced is poorly understood. Here, we show that an MHC class I epitope (SL8) sequence inserted in the second intron of the β-globin gene in a C57BL/6 mouse (HBB) generates immune tolerance. Introduction of SL8-specific CD8

Indexed as

Histocompatibility Antigens Class IRNA PrecursorsAnimalsAntigen PresentationCD8-Positive T-LymphocytesEpitopesHistocompatibility Antigens Class IIImmune ToleranceMiceMice, Inbred C57BLPeptidesProtein BiosynthesisEpitopesHistocompatibility Antigens Class IHistocompatibility Antigens Class IIPeptidesRNA Precursorsimmune toleranceMHC class I antigen presentationmRNA translation

Identifiers

PMID36745791
PMCPMC9963070
OpenAlexW4319303635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.